MPR Weekly Dose 135 — Makena Panel Vote; Apixaban vs Rivaroxaban; Monkeypox Ocular Complications; Novavax COVID-19 Booster; Sparsentan, Tofersen Reviews Extended

<p><span style="font-weight: 400;">FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended.</span></p>